Official Website: CaLycia Biosciences
source confidence: Medium status: Useful updated 2026-06-19
Summary
CaLycia Bioscience's official website describes a Salt Lake City biotechnology company developing macrophage cell therapies for central nervous system solid tumors, with local intracranial delivery designed to bypass blood-brain-barrier limits. The site outlines a four-step platform (engineer, infiltrate, remodel, scale) and a pipeline led by CALYM-001 for glioblastoma at pre-IND stage.
Useful Claims
- The company describes itself as a Salt Lake City-based biotechnology company developing novel macrophage cell therapies for the central nervous system.
- The thesis is that engineered macrophages can infiltrate, remodel, and treat aggressive solid tumors of the brain, leveraging macrophage biology rather than systemic T-cell approaches.
- Local administration into the brain is the stated delivery strategy, bypassing systemic barriers including the blood-brain barrier and immunosuppressive intracranial tumor microenvironments.
- Four mechanism pillars are listed: local delivery (direct CNS administration), innate migration (macrophage motility through tissue margins), phagocytic clearance (engulfment and destruction of tumor cells), and antigen presentation (local tumor-antigen processing to recruit adaptive immunity).
- The platform process is described as: (1) engineer patient macrophages with targeting receptors and immune-activating payloads, (2) infiltrate via localized administration, (3) remodel the microenvironment by engulfing cancer cells and presenting antigens to recruit T-cells, (4) scale via short, high-yield ex vivo manufacturing protocols for primary macrophages.
- CALYM-001 (glioblastoma) is the lead intracranial program, listed at in vivo validation with pre-IND as the next milestone.
- CALYM-002 (melanoma brain metastasis) is a platform-extension program in early discovery.
- The site states the company has robust in-vitro and in-vivo datasets and a scalable ex-vivo production base, and offers secure data-room access to qualified institutional investors and strategic partners for seed-financing discussions.
Verbatim
"We are a Salt Lake City-based biotechnology company developing novel macrophage cell therapies." — Home page, heading
"By leveraging the unique biology of macrophages, we are engineering solutions specifically designed to infiltrate, remodel, and treat aggressive solid tumors of the brain." — Home page, introductory copy
"Our approach uses local administration into the brain, bypassing systemic barriers entirely." — Home page, "Overcoming the Limits of CNS Drug Delivery"
"Modifying the patient's own macrophages with specific targeting receptors and persistent immune-activating payloads to dictate anti-tumor behavior." — Home page, platform step 1
"Robust In-Vitro & In-Vivo Datasets" — Home page, pipeline footer
Reliability Notes
This is an official company marketing site. Preclinical performance, manufacturing yields, regulatory timelines, and financing status are company assertions until confirmed in peer-reviewed publications, IND filings, or independent investor disclosures. The site does not name founders, investors, or academic lab origins on the pages reviewed.